stockrowCRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
Follow CRSP
Alert me
CRISPR Therapeutics AG (CRSP) EV/FCF
As of 6 November 2026, CRISPR Therapeutics AG (CRSP) trades at a EV/FCF of −8.3×. Over the past ten years it has ranged from −64.9× (December 2020) to 188× (December 2019); the current reading is higher than 50% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −8.6× | — |
| FY2024 | −11.4× | — |
| FY2023 | −14.0× | — |
| FY2022 | −3.0× | — |
| FY2021 | 7.8× | — |
| FY2020 | −32.9× | — |
| FY2019 | 48.3× | — |
| FY2018 | −9.2× | — |
| FY2017 | −9.9× | — |
| FY2016 | 0.7× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −9.7× | — |
| Jun 2026 | −9.4× | — |
| Mar 2026 | −6.8× | — |
| Dec 2025 | −8.6× | — |
| 38 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| MANE Veradermics Incorporated compare | −38.8× |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −30.6× |
| DNTH Dianthus Therapeutics, Inc. compare | −23.4× |
| ERAS Erasca, Inc. compare | −16.6× |
| DFTX Definium Therapeutics, Inc. compare | −15.7× |
| COGT Cogent Biosciences, Inc. compare | −15.6× |
| EWTX Edgewise Therapeutics, Inc. compare | −15.5× |
| CRSP CRISPR Therapeutics AG | −8.3× |
| TVTX Travere Therapeutics, Inc. compare | 56.8× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on CRSP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement